What Is Tirzepatide?

Tirzepatide is a laboratory-made molecule that copies two of your gut's meal-time hormones at once. It switches on the receptor for GLP-1, the hormone semaglutide copies, and it also switches on the receptor for a second hormone called GIP. One molecule, two messages. It is the active ingredient in prescription medicines approved for type 2 diabetes and for weight management in certain adults.

Our page on semaglutide explains how a single gut hormone was copied and made to last a week. This page starts from there and asks what changes when you copy two. The short version is that the second hormone, GIP, is the one most people have never heard of, and it is the part that makes tirzepatide different.

Meet the second hormone: GIP

A hormone is a chemical message carried in the blood from one part of the body to another. Your gut makes quite a few of them. Two belong to a small group called incretins. An incretin is a gut hormone, released when food arrives, that tells the pancreas to release more insulin — insulin being the hormone that moves sugar out of the blood and into cells 1.

Scientists noticed something odd long before they knew why. Sugar swallowed by mouth makes the pancreas release far more insulin than the same amount of sugar put straight into a vein. The difference is the gut talking to the pancreas. When food passes through the intestine, cells in its lining release incretins, and those hormones turn up the insulin response in advance of the sugar arriving 1. This is called the incretin effect.

GIP stands for glucose-dependent insulinotropic polypeptide. Take it apart and it is not so bad. Glucose-dependent means it only works when blood sugar is raised. Insulinotropic means it encourages insulin release. Polypeptide means a chain of amino acids, the building blocks of proteins. GIP was actually the first incretin to be found, and it comes from cells in the very first stretch of the small intestine, just after the stomach. GLP-1 comes from a little further along 1.

So your body already runs a two-part system. After a meal, two gut hormones arrive at the pancreas at roughly the same time, each with its own receptor, each nudging insulin up. The older medicines copied only one of them. Tirzepatide was designed to copy both.

How do you build one molecule that does two jobs?

A receptor is a structure on the outside of a cell shaped to catch one particular molecule. Normally, the GIP receptor catches GIP and the GLP-1 receptor catches GLP-1. The two hormones are related, a bit like cousins who share some family features, so their receptors are related too. That family resemblance is what made a two-in-one molecule possible.

The designers started from the GIP chain and changed some of its building blocks so that the result could also fit the GLP-1 receptor well enough to switch it on 2. Think of a key cut so that it opens two neighbouring doors in the same building. Neither door was changed. The key was shaped to suit both.

Then they borrowed the same trick semaglutide uses to last. A fatty tail was attached to the chain, which lets the molecule hold on loosely to albumin, the most common protein in blood. While it holds on, it is too big for the kidneys to filter out and harder for enzymes to cut 2. Enzymes are proteins whose job is to take other molecules apart. The result lasts about five days in the blood, which is why it can be given once a week.

Does it act on both receptors equally?

No, and this is one of the more interesting things about it. When researchers measured how tightly and how strongly tirzepatide works at each receptor, they found it behaves very much like natural GIP at the GIP receptor, but noticeably more weakly than natural GLP-1 at the GLP-1 receptor 3. They called it imbalanced. It leans towards GIP.

They also called it biased, which needs a word of explanation. When a receptor is switched on, the cell can respond in more than one way, a bit like a light switch that can also ring a doorbell. At the GLP-1 receptor, tirzepatide favours one of those responses over another, and one practical result is that the receptor is pulled back inside the cell less often 3. A receptor that stays on the surface stays available to be switched on again.

Why does any of that matter to you? Mainly because it shows that "copies two hormones" is a simplification. The molecule is not half GIP and half GLP-1. It has its own particular balance, and that balance is part of what was designed.

How is it different from semaglutide, in one paragraph?

Semaglutide copies one hormone, GLP-1, and is built on the GLP-1 chain. Tirzepatide copies two, GIP and GLP-1, and is built mainly on the GIP chain. Both use a fatty tail to last about a week. When the two were compared directly in people with type 2 diabetes, tirzepatide lowered blood sugar more than the version of semaglutide it was compared against, and body-weight change was larger too 5. That is one trial, in one group of people, against one strength of the other medicine. It is a real result, but not a verdict on every situation.

What did the main obesity trial look at?

The first large trial of tirzepatide in adults with obesity or overweight, without diabetes, enrolled about two and a half thousand people. They were assigned by chance to one of three strengths of tirzepatide or to a placebo, an inactive look-alike, alongside the same advice on diet and activity. Neither the participants nor the researchers knew who was getting what 4.

After seventy-two weeks, average body-weight change was about a fifth of starting weight in the highest arm, against about three percent in the placebo group 4. The lower arms changed less. Stomach effects such as nausea, diarrhoea and constipation were the most common problems, mostly mild to moderate and most frequent while the amount was being increased at the start 4.

Notice how that result is reported: an average, across a large group, compared against a placebo group over a stated time. An average hides a wide spread. Some people changed far more, and some far less. The comparison group is what tells you how much of the change came from the medicine rather than from the advice everyone received.

What is it approved for?

In the European Union, tirzepatide was first authorised in 2022 for adults with type 2 diabetes that is not well controlled, alongside diet and exercise, and its authorisation also covers weight management in adults with obesity, or overweight plus a weight-related health problem 6. In the United States, a separate product was approved in 2023 specifically for chronic weight management in the same kind of adults. The regulator described it as switching on the receptors for both gut hormones to reduce appetite and food intake 7.

As with any medicine, the approval belongs to a specific manufactured product for a specific purpose. It does not transfer to anything else that happens to carry the name.

What is still not known?

Here is the honest puzzle. For years, GIP looked like the less useful incretin, because in people with type 2 diabetes its effect on insulin seemed weaker. Then a molecule that leans heavily on GIP turned out to lower blood sugar and body weight more than a molecule that copies GLP-1 alone. Stranger still, other research groups have found that blocking the GIP receptor, rather than switching it on, can also go along with body-weight change in some studies.

Both switching on and blocking the same receptor seeming to point the same way is the sort of thing that makes scientists sit up. There are several possible explanations, involving how receptors respond to being switched on for long periods and where in the body they sit. None has been settled. So when you read that the GIP half of tirzepatide is responsible for its extra effect, treat that as a reasonable idea still being tested, not an established fact 3.

What tirzepatide is not

• It is not two drugs mixed together. It is one molecule that fits two receptors.
• It is not an equal copy of both hormones. It leans towards GIP.
• It is not insulin, and it does not force insulin release. Both hormones it copies work only when blood sugar is raised.
• It is not the same thing as material sold under its name as a research substance. That material has not been assessed by any regulator and is not what the trials tested.

The short version

Your gut sends two meal-time messages to the pancreas, GIP and GLP-1. Tirzepatide is one molecule shaped to deliver both, leaning more on the first, and built to last a week. That single idea, two receptors from one molecule, is the whole of what separates it from semaglutide. The next step along the same road adds a third receptor, and that molecule is still in trials.